Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

Cancer

Volumn 92, Issue 2, 2001, Pages 406-413

  Giles, Francis J ^a   Kantarjian, Hagop M ^a   Kornblau, Steve M ^a   Thomas, Deborah A ^a   Garcia Manero, Guillermo ^a   Waddelow, Tracey A ^a   David, Cynthia L ^a   Phan, Alexandria T ^a   Colburn, Dawn E ^a   Rashid, Asif ^a   Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; Gemtuzumab ozogamicin; Hepatic venoocclusive disease; Hepatotoxicity; Mylotarg

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; INTERLEUKIN 11; TROXACITABINE; UNCLASSIFIED DRUG; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER VEIN OBSTRUCTION; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; ADOLESCENT; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INCIDENCE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0035878068     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U     Document Type: Article

References (51)

1. Venoocclusive disease of the liver following bone marrow transplantation
2. Veno-occlusive disease of the liver
3. The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation
4. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
5. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas
6. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma
7. Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases
8. Veno-occlusive disease-like hepatotoxicity in two children receiving chemotherapy for Wilms' tumor and clear cell sarcoma of kidney
9. Veno-occlusive disease of the liver in children following chemotherapy for acute myelocytic leukemia
10. Pathophysiological aspects of dacarbazine-induced human liver damage
11. Hepatic veno-occlusive disease caused by 6-thioguanine
12. 6-Thioguanine as a cause of toxic veno-occlusive disease of the liver
13. Actinomycin D associated hepatic veno-occlusive disease: A report of 2 cases
14. Veno-occlusive disease of the liver associated with thiopurines in a child with acute lymphoblastic leukemia
15. High incidence of veno-occlusive disease related to indicine N-oxide in the treatment of refractory adult acute leukemia
16. Monoclonal antibodies to the myeloid stem cells: Therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate
17. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
18. Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676): Relationship to hematopoietic stem cell transplantation
19. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors
20. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial
21. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients
22. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders
23. Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study
24. The syndrome of hepatic veno-occlusive disease after marrow transplantation
25. Differential expression of surface antigens on activated endothelium
26. Antibody therapy of acute myelogenous leukemia
27. Antibody-targeted therapy for myeloid leukemia
28. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia
29. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia
30. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia
31. Phase 1 study of irofulven (MGI- 114), an acylfulvene illudin analog, in patients with acute leukemia
32. Acute radiation-induced hepatic injury: Evaluation by triphasic contrast enhanced helical CT
33. Color-flow imaging sonography of portal and hepatic vein flow to monitor flbrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment
34. Grossly abnormal liver-spleen scan in a patient with veno-occlusive disease of the liver that normalized completely on follow-up
35. MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation
36. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells
37. Solution structure of the calicheamicin gamma II-DNA complex
38. Regulation of apoptosis in leukemic cells by analogs of dynemicin A
39. DNA bending is a determinant of calicheamicin target recognition
40. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma
41. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics
42. Calicheamicin gamma II: An antitumor antibiotic that cleaves double-stranded DNA site specifically
43. The pharmacokinetics of gemtuzumab ozogamicin: An antibody-targeted chemotherapy agent for relapsed acute myeloid leukemia
44. Support of sinusoidal endothelial cell glutathione prevents hepatic reno-occlusive disease in the rat
45. Supercoiling affects the accessibility of glutathione to DNA-bound molecules: Positive supercoiling inhibits calicheamicin-induced DNA damage
46. Enediyne-mediated DNA damage in nuclei is modulated at the level of the nucleosome
47. Exclusive production of bistranded DNA damage by calicheamicin
48. Induction of hepatic veno-occlusive disease in dogs
49. Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer
50. CD19 targeted calicheamicin is effective against high risk ALL
51. Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation